- Home
- IVA vs GLQ Comparison
IVA vs GLQ Comparison
Compare IVA & GLQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- GLQ
- Stock Information
- Founded
- IVA 2011
- GLQ 2005
- Country
- IVA France
- GLQ United States
- Employees
- IVA N/A
- GLQ N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- GLQ Finance/Investors Services
- Sector
- IVA Health Care
- GLQ Finance
- Exchange
- IVA Nasdaq
- GLQ Nasdaq
- Market Cap
- IVA 117.3M
- GLQ 126.1M
- IPO Year
- IVA 2020
- GLQ N/A
- Fundamental
- Price
- IVA $2.17
- GLQ $6.92
- Analyst Decision
- IVA Strong Buy
- GLQ
- Analyst Count
- IVA 4
- GLQ 0
- Target Price
- IVA $13.25
- GLQ N/A
- AVG Volume (30 Days)
- IVA 6.4K
- GLQ 65.5K
- Earning Date
- IVA 09-25-2024
- GLQ 01-01-0001
- Dividend Yield
- IVA N/A
- GLQ 11.11%
- EPS Growth
- IVA N/A
- GLQ N/A
- EPS
- IVA N/A
- GLQ N/A
- Revenue
- IVA $20,652,523.00
- GLQ N/A
- Revenue This Year
- IVA N/A
- GLQ N/A
- Revenue Next Year
- IVA $361.78
- GLQ N/A
- P/E Ratio
- IVA N/A
- GLQ N/A
- Revenue Growth
- IVA N/A
- GLQ N/A
- 52 Week Low
- IVA $1.53
- GLQ $5.13
- 52 Week High
- IVA $4.50
- GLQ $6.54
- Technical
- Relative Strength Index (RSI)
- IVA 39.56
- GLQ 61.40
- Support Level
- IVA $2.11
- GLQ $6.60
- Resistance Level
- IVA $2.24
- GLQ $6.84
- Average True Range (ATR)
- IVA 0.07
- GLQ 0.07
- MACD
- IVA 0.01
- GLQ 0.03
- Stochastic Oscillator
- IVA 26.58
- GLQ 97.22
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.